Haifa, Israel – December 9, 2025 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the Company’s largest shareholders, has been appointed Chairman of the Board of Directors. The appointment reflects the Board’s view that Mr. Weinstein brings a decisive, business driven perspective that aligns with Pluri’s objectives of strengthening market positioning and accelerating the recognition and realization of the significant value embedded in the Company’s underlying assets.
“I am honored to take on the role of Chairman and am fully committed to make the strategic changes needed for driving Pluri into its next stage of growth,” said Alejandro Weinstein. “Pluri has a strong platform, promising commercial pathways, and a portfolio of assets that I believe hold significant untapped potential. Together with the management team, I look forward to building on the Company’s solid foundation, advancing key priorities, and further strengthening strategic initiatives that can unlock the substantial value inherent in our underlying assets, and drive long-term value. I also want to thank Mr. Aberman for his long-standing leadership and meaningful contribution to Pluri’s foundation.”
Mr. Weinstein, a prominent investor, has built and scaled global companies across healthcare, biotechnology, and wellness, including transforming CFR Pharmaceuticals into a multinational group later acquired by Abbott for $2.9 billion, and founding leading investment platforms such as WM Partners, Olive Tree Ventures, and Vanterra Ventures, which is active in functional food and nutrition innovation. His proven ability to grow companies, execute strategic transactions, and lead value driven organizations makes him a strong candidate to serve as Chairman.
As part of this leadership evolution, Mr. Zami Aberman, who has served as Pluri’s Chairman for two decades, will transition into the role of Vice Chairman and continue to support the Company’s strategic direction.
“It has been a privilege to serve as Chairman and to help guide Pluri through key stages of its development,” says outgoing Chairman Zami Aberman.
“Alejandro’s increased involvement reflects the strong potential ahead and his approach to value creation. As I transition into the role of Vice Chairman, I look forward to supporting Pluri’s continued progress and ensuring a smooth leadership transition.”
Yaky Yanay, Chief Executive Officer and President of Pluri, commented: “Mr. Weinstein’s increased investment and appointment as Chairman reflect a clear belief in our direction and mark the beginning of a new phase for Pluri. I want to sincerely thank Mr. Aberman for his leadership over the past two decades and for his continued support as Vice Chairman. With Mr. Weinstein now taking the Chairman role, we are focused on sharpening execution, accelerating commercialization, and unlocking the significant value within our platform and ventures for the benefit of our shareholders and strengthening our position for the years ahead.”
In addition to this leadership transition, Pluri has entered into a Securities Purchase Agreement with an entity beneficially owned by Mr. Weinstein. Pursuant to the agreement, the investor will purchase 625,000 Pluri common shares, together with warrants to purchase up to an additional 625,000 common shares in a private placement, at a combined purchase price of $4. The warrants have an exercise price of $4.25 per share, are exercisable immediately and will be exercisable until June 30, 2026. The transaction is expected to generate aggregate gross proceeds of approximately $2.5 million. Pluri intends to use the proceeds from the private placement for general working capital.
The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, or applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions.
The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its objectives of strengthening market positioning, sharpening its commercial execution, and accelerating recognition and realization of the value embedded in its underlying assets, that Pluri has real commercial opportunities and a portfolio of assets that are undervalued by the market, that the Company’s ventures represent meaningful strategic potential, Pluri’s focus on sharpening execution, advancing commercialization and building long-term value for its shareholders, and the expected use of proceeds from the private placement. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Haifa, Israel – November 13, 2025 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell‑based solutions through a collaborative network of ventures, today announced that the Company and its subsidiaries have received multiple awards recognizing excellence in innovation, scientific achievement, and industry leadership.
Pluri was named Overall BioAgriculture Company of the Year by the Biotech Breakthrough Awards last week, highlighting its pioneering work of applying cell therapy and derived technologies to agriculture and sustainable food systems. The award underscores Pluri’s progress in developing scalable cell-based solutions that extend biotechnology’s impact beyond human health into new market sectors.
Pluri’s subsidiaries also achieved other significant industry recognition:
In addition, Israel’s Ministry of Labor, Social Affairs and Social Services has selected Pluri as the winner of the 2024 Egalitarian Employment Award in the Large Company category. Pluri’s Chief Executive Officer and President, Yaky Yanay, is expected to accept the award from Nir Barkat, Israel’s Minister of Economy and Industry, at a ceremony next month in Jerusalem. The Company is also expecting to receive a government grant of 40,000 NIS along with the award. Pluri was also recently listed on Dun’s 100 list of Best HighTech Companies to work for in 2025.
These recognitions reinforce Pluri’s position as a biotechnology leader developing patented and validated, high-value technologies with the potential to transform multiple industries. The Company’s proprietary 3D cell expansion platform enables the development and manufacturing of cell-based products at commercial scale, serving as the foundation for partnerships and ventures in regenerative medicine, food and agtech.
“These awards reflect the strength and versatility of Pluri’s platform, as well as the market confidence in our strategy to apply cell-based innovation across multiple industries,” said Mr. Yanay. “We are proud that our subsidiaries are also being recognized for turning breakthrough science into scalable business solutions that address global challenges in agriculture and food security.”
About Pluri Inc.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, aesthetics and offers Contract Development and Manufacturing Organization services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Forward-Looking Statements
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Pluri’s expectation to receive the Israel’s Ministry of Labor, Social Affairs and Social Services award and the government’s grant of 40,000 NIS, and its technologies’ potential to transform multiple industries. . These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
Haifa, Israel (November 11, 2025) – Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the launch of Cellav Health and Aesthetics Ltd. (“Cellav”), its wholly-owned health and aesthetics subsidiary, focused on developing science-driven and regenerative solutions powered by Pluri’s proprietary 3D cell expansion platform. The launch follows Cellav’s first secured commercial collaboration with Miss Universe Skincare (“Miss Universe Skincare”), a global skincare and beauty brand. The collaboration will focus on the co-development of a new line of advanced, cell-based skincare products.
Cellav is expected to supply a proprietary cell-based active ingredient, developed using Pluri’s cell expansion platform, for use in a new series of skincare products expected to be launched under the Miss Universe Skincare label. The first product is expected to launch during the first half of 2026 and will be distributed through Miss Universe Skincare’s global platform. The official presentation of this collaboration is expected to take place during the pre-gala activities of the 74th Miss Universe event in Thailand. This collaboration marks a major milestone in Pluri’s strategy to expand into high-growth, revenue-generating markets. Cellav’s solutions combine regenerative biotechnology with the global appeal of beauty and wellness to meet rising consumer demand for credible, science-based skincare. Derived from various cell sources and manufactured under the highest quality standards, Cellav’s exosomes are designed to enhance skin rejuvenation, elasticity, and radiance.
“At Miss Universe Skincare, we believe that true beauty begins at the cellular level,” said Olivia Quido, President of Miss Universe Skincare and Vice President of Global Partnerships, Miss Universe Organization. “Through our collaboration with Cellav by Pluri, we are proud to introduce the extraordinary benefits of exosome technology – one of the most advanced frontiers in skincare science. Exosomes derived from regenerative biotechnology help boost skin rejuvenation, enhance elasticity, and restore natural luminosity. By integrating these powerful actives into our formulations, we continue our mission to empower every individual to glow with confidence, vitality, and purpose.”
Cellav is led by Chief Executive Officer Katty Dowery, a pharmaceutical engineer and biotechnology executive with over a decade of experience in cell-based technologies, regenerative medicine, and product innovation. As a long-time leader within Pluri, she brings a strong track record of translating advanced science into commercial success.
“At Cellav, we’re bridging advanced biotechnology with the world of beauty,” said Ms. Dowery. “Through my work with cells and regenerative medicine, I’ve seen the remarkable potential of this science. I believe it shouldn’t remain confined to laboratories or clinical research – it should enhance how we look, feel, and live every day. Our mission is to make regenerative science accessible and impactful. What sets us apart is our scientific integrity, deep cell-based technology expertise, and commitment to the highest quality standards. We believe the future of beauty lies in regenerative biotechnology, and with Pluri’s platform behind us, we’re ready to lead the way.”
“Our partnership with Miss Universe Skincare marks more than just a strategic brand collaboration- it’s a clear step forward in Pluri’s focused strategy to apply our platform where we believe our technology can make the greatest impact,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “By launching Cellav, we are expanding into a high-demand market with a differentiated, science-driven offering—one that aligns with our commitment to near-term revenue generation, scalable innovation, and advancing global wellbeing.”
About Cellav
Cellav is Pluri’s subsidiary, dedicated to transforming cutting-edge cell science into high-impact solutions for health and aesthetics. At its core, Cellav is built to bridge science and real-world results-delivering flexible, business-to-business offerings that meet the growing demand for regenerative, credible, and customizable beauty innovations. Cellav plans to operate through three core areas: (i) Cellav develops premium cell-derived ingredients- such as exosomes and cell extracts—that can be integrated into partner formulations or devices; (ii) Cellav offers professional-use and consumer-ready skincare and haircare products powered by regenerative actives; and (iii) Cellav provides a flexible technology platform that enables partners to scale production, co-develop innovative solutions, and launch white-label or co-branded products. Cellav intends to work with global beauty brands, device manufacturers, medical clinics, and distributors. Its business model is intentionally adaptable, supporting licensing, joint ventures, and royalty-based collaborations. All offerings are backed by over two decades of Pluri’s expertise, rooted in pharmaceutical-grade development and designed to scale with partners around the world. Learn more at visit: https://pluri-biotech.com/revolutionizing-the-beauty-industry/
About Miss Universe Skincare
Miss Universe Skincare, the official skincare line inspired by the Miss Universe brand, combines science and luxury to empower individuals to glow with confidence and purpose. Each formula features the proprietary MU7C+ Complex, a blend of age-defying actives sourced from seven continents, and innovative drone-delivery technology designed to optimize efficacy and achieve luminous, even-toned skin. Founded and led by Olivia Quido, President of Miss Universe Skincare and Vice President of Global Partnerships, Miss Universe Organization, Miss Universe Skincare reflects a legacy of excellence, global reach, and professional trust. Its products have been selected as the official skincare regimen used by Miss Universe contestants worldwide. Together with Cellav by Pluri, Miss Universe Skincare continues to elevate the standards of modern skincare through innovation, integrity, and results-driven beauty science. To learn more, visit http://www.missuniverseskincare.com
About Pluri
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, aesthetics and offers Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Cellav’s platform and development capabilities, dedication and ability to deliver solutions and technologies for medical aesthetics, including by leveraging Pluri’ platforms; projections of the beauty markets; the development of a new line of skincare products as part of the collaboration and the expected timeline and location of the first product launch; Cellav’s ability to supply the ingredients under the agreement; Pluri’s ability to expand into high-growth and revenue-generating verticals; the exosomes’ abilities; the expectations from Cellav’s Chief Executive Officer; Cellav’s products’ ability to deliver measurable results; the potential impact of Pluri’s technology; the expectation that Pluri will expand into a high-demand market; the expectation of revenue-generation; and Pluri’s continued ability to accelerate breakthroughs that address global challenges. These forward-looking statements and their implications are based on the current expectations of Pluri and Cellav’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the collaboration may not be realized as anticipated; Pluri may encounter changes in technology or market conditions; Pluri and Cellav may face challenges in launching or scaling new products and product lines; regulatory developments could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; unforeseen scientific or operational challenges; and intensified competition in the medical aesthetics and wellness space. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Berry Brady at berry@quantum-corp.com
Haifa, Israel – November 10, 2025 – Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell‑based solutions through a collaborative network of ventures, has entered into a series of significant international collaborations across its foodtech and agtech subsidiaries. These collaborations represent a major step forward in Pluri’s mission to transform food and agriculture production through its advanced 3D cell-expansion technology and scalable innovations.
Pluri’s three subsidiaries, Ever After Foods Ltd. (“Ever After Foods”), Kokomodo Ltd. (“Kokomodo”), and Coffeesai Ltd. (“Coffeesai”), have signed collaboration agreements with key global food and agtech leaders in Asia, Europe, and the U.S. We believe this expansion reflects both increasing commercial viability and rising global demand for sustainable, cell-based innovations.
“These collaborations represent a major leap forward in our foodtech and agtech roadmap,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “We believe that each collaboration not only validates the market readiness and multifaceted potential of our scalable 3D cell expansion technologies but also brings the power of world-class collaborators into our ecosystem. Together, we aim to reshape the way the world produces and consumes essential food products. We believe that the fact that every agreement includes a collaborator-funded proof-of-concept (“POC”) is a clear vote of confidence in our technology and reinforces our ability to deliver sustainable, long-term value for our shareholders.”
Pluri’s momentum comes at a critical moment, with demand for sustainable solutions for traditional agriculture on the rise amid challenges such as warming climates, dwindling natural resources, and an increasing global population. By leveraging its proprietary 3D cell expansion platform, Pluri’s technology enables rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints.
About Pluri Inc.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers Contract Development and Manufacturing Organization services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
Forward-Looking Statements
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Pluri’s subsidiaries’ expansion of market presence; the expansion of strategic collaborations reflecting both increasing commercial viability and rising global demand for sustainable, cell-based innovations; Ever After Foods’ ability to advance scale-up validation and pre-commercial trials on collaborator use cases, turn pipeline into pilot results and de-risk technical pathways; Ever After Foods’ position to scale while maintaining disciplined spend; Ever After Food’s ability to meet milestones such as pilot results and expansion of collaborator programs in priority markets, including opening go-to-market options and supporting long-term sustainability and food security; Kokomodo’s collaborations’ goal to enable it to expand its research, development, and manufacturing capabilities while exploring co-development opportunities across Europe and North America; the ability to accelerate Coffeesai’s mission to deliver eco-friendly, resource-efficient cellular coffee production through cell cultivation and minimize the environmental toll of traditional farming while simplifying complex logistics by bringing production closer to consumers; the belief that the collaboration validate the market readiness and multifaceted potential of our scalable 3D cell expansion technologies and brings the power of world-class partners into Pluri’s ecosystem; Pluri’s goal to reshape the way the world produces and consumes essential food products; the belief that the fact that every collaboration includes a partner-funded POC is a vote of confidence in Pluri’s technology and reinforces Pluri’s ability to deliver sustainable, long-term value for its shareholders and by leveraging its proprietary 3D cell expansion platform; and Pluri’s technology ability to enable rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
Haifa, Israel (October 8, 2025) — Pluri Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell‑based solutions through a collaborative network of ventures, today announced that Coffeesai Ltd. (“Coffeesai”), its wholly owned subsidiary developing sustainable cell‑based coffee products, has signed an agreement with the Instituto del Café de Chiapas (INCAFECH), a public body of the State of Chiapas, Mexico, to advance cell‑based coffee manufacturing in Mexico.
Under the collaboration agreement, the parties aim to progress along a three‑phase roadmap designed to de‑risk commercialization:
Why Chiapas, why now: Chiapas is Mexico’s leading coffee‑growing region, and Mexico is among the world’s top coffee‑producing countries. Pluri believes that establishing operations in Chiapas positions the state as a hub for cell‑based coffee innovation, blending cutting‑edge biotechnology with a deep local coffee tradition.
Structured to Create Tangible Shareholder Value
Leadership Commentary
“The State of Chiapas has always been a leader in coffee production, and now we aim to lead in coffee innovation,” said Jorge Baldemar Utrilla Robles, Director of the Instituto del Café de Chiapas. “By partnering with Coffeesai and Pluri, we are bringing cutting‑edge biotechnology to our region, strengthening our farmers’ future, creating jobs, and positioning Chiapas as a global reference point for the future of coffee.”
“Coffeesai is ready to execute,” said Ami Herman, Chief Executive Officer of Coffeesai. “We will immediately begin Phase 1 by establishing and validating cell lines in Chiapas, followed by pilot‑scale deployment of our bioreactors. Each milestone brings us closer to a commercial model that establishes Coffeesai as a leader in sustainable coffee production.”
“We are building the foundation for cost‑competitive, commercial‑scale cell‑based coffee production in Mexico,” said Yaky Yanay, Chairman of Coffeesai and Chief Executive Officer and President of Pluri. “This collaboration is not only about innovation; it is about creating a revenue‑generating model aligned with our shareholders’ interests while transforming the future of coffee.”
About Pluri Inc.
Pluri™ is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.
About Coffeesai
Coffeesai is Pluri’s cell-based coffee subsidiary, creating cell-based coffee in labs rather than traditional fields and eliminating the negative environmental impact associated with conventional coffee farming. Coffee consumption has surged by 60% in the last 30 years, resulting in significant environmental damage, including deforestation, increased water usage, and extensive pesticide use. Coffeesai offers a revolutionary solution to this problem, providing a sustainable alternative to traditional coffee production. The innovative process mimics nature without exploiting it, ensuring consistent quality and high yields while using minimal resources.
About Instituto del Café de Chiapas
The Instituto del Café de Chiapas is a decentralized public body of the State of Chiapas, Mexico, dedicated to advancing coffee production, supporting local farmers, and fostering innovation. Chiapas produces more than 40% of Mexico’s coffee, cementing its role as the country’s leading coffee region.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses Coffeesai’s technology and its abilities to leverage Pluri’s platform and expertise; the global coffee market size projections; Pluri’s ability to maintain its collaboration with the Instituto del Café de Chiapas and accomplish successfully, or at all, the collaboration three-phase roadmap; Chiapas positioning as a hub for cell-based coffee innovation and its leadership in coffee innovation; the partnership’s potential as a blend of biotechnology and tradition and its ability to drive the advancement of cell-based coffee manufacturing; the expected future shareholders value creation through license and technology transfer, recurring revenue streams, market expansion and ESG; the belief that the partnership will bring cutting-edge biotechnology to the State of Chiapas, strengthen farmers’ future, create jobs, and position Chiapas as a global reference point for the future of coffee; the expectation to immediately begin the first phase of cell line development followed by the second phase of pilot-scale deployment of biocreators; the expectation that Coffeesai will be positioned as a leader in sustainable coffee production; and the collaboration’s ability to create a revenue-generating model and to transform the future of coffee. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the completed collaboration may not be realized as anticipated; changes in technology or market conditions; Pluri may face challenges in launching or scaling new products; government approvals and regulatory developments could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; unforeseen scientific or operational challenges; weather conditions may affect production; and intensified competition in the cultivated food space. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
U.S. Media: Berry Brady at berry@quantum-corp.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
HAIFA, Israel – May 15, 2025 – Pluri Inc. (Nasdaq, TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer and President, Yaky Yanay:
Dear Shareholders,
As we conclude our fiscal year, which was marked by challenges and accomplishments, I’m pleased to share key developments and to outline our path forward. Pluri is aiming to lead a global biotech revolution in the fields of healthcare, food, and agriculture by leveraging our innovative cell expansion platform. This platform enables us to grow cells from diverse sources and transform them into pharmaceuticals, food products, and agricultural goods to address many multi-billion dollar markets.
We anticipate that the coming fiscal year will mark a significant turning point, as we unlock the potential of our cell expansion technology to deliver scalable global solutions — particularly in the cocoa and coffee industries, where climate change, plant diseases, and rising demand are steadily increasing shortages. The technological and managerial expertise we’ve accumulated, combined with the economic potential in these sectors, positions Pluri with a strategic edge. We believe that one of our key strengths lies in our ability to produce cells at a commercial scale — independent of weather and location — within compact, sustainable facilities. We believe that our capability to assemble cells into finished products — such as cultivated meat, coffee and cocoa — will enable us to meet global demand while maintaining consistent quality and competitive pricing. Notably, our products closely resemble their natural counterparts and involve no genetic engineering whatsoever.
As part of our growth strategy, we have taken steps to strengthen our position in the cultivated cacao space by aligning with an Israeli AgFoodTech company that is developing innovative cell-based cacao technology. Led by a talented team of entrepreneurs and scientists, the company has made promising progress in producing cacao directly from cells, while maintaining the taste, functionality, and nutritional integrity of the original product. The global cacao industry is facing increasing pressure due to climate change, disease, and unsustainable farming practices, making it critical to develop reliable and environmentally responsible alternatives. This initiative supports our broader vision of expanding into high-impact sectors and advancing sustainable, vertically integrated solutions in the cultivated food industry.
We are also fortunate to have the backing of strategic investors who share our long-term vision and recognize the global potential of our technology. Recently, we secured additional investment from a new partner with deep expertise in healthcare and a strong track record in emerging markets. This support does not only reinforce our financial position but also enhances our ability to expand into key geographies where our solutions can have meaningful impact.
In addition, we hold a 69% stake in Ever After Foods Ltd., a private company leveraging Pluri’s cell expansion technology for cultivated meat production. Ever After Foods was founded by Pluri in partnership with Tnuva, which initially invested $7.5 million. In June 2024, two major international strategic partners — one from the food sector and the other from FoodTech — led a $10 million funding round in Ever After Foods.
On the medical research front, we received a total of $2.2 million in funding to date from the U.S. National Institutes of Health and the Department of Defense to develop PLX-R18 for the treatment of Acute Radiation Syndrome (ARS). This funding was reflected as a reduction in research and development expenses. Due to federal budget cuts, such funding has been discontinued, and we are currently working to secure alternative support from several partners. In parallel, we signed a collaboration with Hemafund Ltd. to develop nuclear emergency response plans in Ukraine and Europe, drawing on our accumulated experience.
Financially, in the first nine months of our fiscal year 2025, we recorded a fourfold increase in revenue — from $230,000 in the same period in fiscal year 2024, to $938,000. This growth is primarily attributed to the launch of new business verticals, specifically in the Contract Development and Manufacturing Organization field and an increase related to a proof-of-concept collaboration with a leading international agriculture corporation in the agtech field. While mindful of market dynamics, we remain encouraged by current trends and expect revenue growth to continue as our commercial efforts gain traction.
As we move forward, we are actively positioning the Company for sustained growth, increased revenue streams, and the expansion of our operations. We are currently in discussion with leading players in the cocoa and coffee industries and are exploring opportunities for commercial implementation of our technology — including potential out-licensing to strategic partners.
In conclusion, we believe that Pluri today operates one of the world’s most innovative and diverse cell expansion platforms, with a wide range of activity in critical sectors. We operate in vast markets characterized by instability and supply chain challenges, and we believe we are uniquely positioned to address these issues. As we approach the end of fiscal year 2025 and the beginning of fiscal year 2026, Pluri moves forward with a solid foundation, strategic partnerships, technological resilience, and a genuine belief in our ability to lead meaningful change in the food and healthcare sectors.
I want to express my gratitude to you — our shareholders, in Israel and around the world — for your continued trust, support, and belief in our shared vision.
Best regards,
Yaky Yanay
Chief Executive Officer and President, Pluri Inc.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, enables the development of novel cell-based solutions to address some of the world’s most pressing challenges—from medicine and climate change to food scarcity and animal welfare. Pluri’s platform is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. The Company operates in the regenerative medicine, foodtech, and agtech sectors and provides Contract Development and Manufacturing Organization services. Through strategic partnerships, Pluri aims to deploy its proprietary 3D cell-based technology across various industries that demand effective and scalable cell production. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its ability to lead a global biotech revolution in healthcare, food and agriculture; its ability to transform cells into pharmaceuticals, food products, and agricultural goods; its expectation that the coming year will mark a significant turning point as it unlocks the potential of their cell expansion technology to deliver scalable global solutions; its positioning with a strategic edge; its ability to produce cells at a commercial scale; its ability to assemble cells into finished products and to meet global demand while maintaining consistent quality and competitive pricing; its ability to expand into key geographies; its ability to secure alternative support from partners following the federal budget cut; its ability to develop nuclear emergency response plans in Ukraine and Europe in collaboration with Hemafund; and its expectation that revenue will continue to grow and its operations will expand.
These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the completed transactions may not be realized as anticipated; Pluri may encounter delays or obstacles in integrating the Israeli AgFoodTech company’s operations; changes in technology or market conditions; Pluri may face challenges in launching or scaling new products; regulatory developments could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; unforeseen scientific or operational challenges; and intensified competition in the cultivated food space.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Berry Brady at berry@quantum-corp.com
HAIFA, Israel – April 28, 2025 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the completion of the acquisition of approximately 71% of the equity of Kokomodo Ltd. (“Kokomodo”), an innovative AgFoodTech company specializing in cultivated cacao production, for $4.5 million payable in 976,139 of the Company’s Common Shares (the “Common Shares” and the “Kokomodo Transaction”, respectively). Kokomodo will continue to operate as an independent company and a subsidiary of Pluri, maintaining its mission, team, and brand identity under the leadership of its Co-Founder and Chief Executive Officer Tal Govrin, while benefiting from being part of the Pluri group.
“We are incredibly excited to join forces with Pluri,” said Tal Govrin, Chief Executive Officer and Co-founder of Kokomodo. “Scaling breakthrough innovation in food requires both technological expertise and market reach. By teaming up with Pluri, we believe that we will gain the ability to accelerate our production capabilities, expand globally, and remain true to our founding mission. I am proud to continue leading Kokomodo and we look forward to demonstrating how cellular agriculture technology can revolutionize the cacao industry with more sustainable, consistent, and adaptable products.”
“At Pluri, we are committed to pioneering sustainable solutions that address critical challenges in the global food industry,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “With the closing of this strategic acquisition, we believe that we are uniquely positioned to lead innovation in the cultivated cacao sector. This acquisition advances our mission of transforming global food systems through biotechnology while adding complementary technology to our portfolio. By combining Pluri’s proven expertise in scalable and cost-effective cell production with Kokomodo’s innovative approach to cultivated cacao, we believe that this acquisition can address growing concerns about climate change impacts on traditional cacao farming, while meeting increasing consumer demand for sustainable cacao-based products.”
According to Grand View Research, the global cacao market was valued at $13.5 billion in 2023 and expected to grow at a CAGR of 8.2% to $23.5 billion by 2030.
About Kokomodo
Kokomodo crafts real, controlled, climate-resilient cacao using cellular agriculture technology, making high-quality cacao accessible globally, all year round. By cultivating cacao directly from plant cells, Kokomodo preserves the rich flavor, functionality, and nutritional qualities of cacao while minimizing the environmental, ethical, and supply chain challenges of traditional production. With a diverse library of cacao cell lines, Kokomodo enables the development of tailored cacao ingredients that are essential for the chocolate industry, while also creating new opportunities for functional ingredients and wellness products. The company is led by Co-Founder and Chief Executive Officer, Tal Govrin, and Chief Technology Officer, Dario Breitel, PhD, and has been recognized by leading global accelerators for its innovation at the intersection of food, wellness, and sustainability. To learn more, visit www.thekokomodo.com or follow Kokomodo on Linkedin.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, enables the development of novel cell-based solutions to address some of the world’s most pressing challenges—from medicine and climate change to food scarcity and animal welfare. Pluri’s platform is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. The Company operates in the regenerative medicine, foodtech, and agtech sectors and provides Contract Development and Manufacturing Organization services. Through strategic partnerships, Pluri aims to deploy its proprietary 3D cell-based technology across various industries that demand effective and scalable cell production. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expected benefits from the completion of the Kokomodo Transaction; the belief that cellular agriculture technology can revolutionize the cacao industry; the expectation that the acquisition will accelerate its production capabilities and expansion into the cultivated cacao market, and support ongoing innovation and strategic growth across its cell-based technology platform; the belief that the acquisition of Kokomodo will enable Pluri to drive growth and expansion of Kokomodo’s operations by leveraging its cultivated cacao solutions to capitalize on growing demand for sustainable food technologies; and the belief that the synergy between Kokomodo’s advancements in cell line development and Pluri’s industrial-scale production will create a strong foundation for innovation and industry leadership in cultivated cacao.
These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the completed transaction may not be realized as anticipated; Pluri may encounter delays or obstacles in integrating Kokomodo’s operations; changes in technology or market conditions; Pluri may face challenges in launching or scaling new products; regulatory developments could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; unforeseen scientific or operational challenges; and intensified competition in the cultivated food space.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Berry Brady at berry@quantum-corp.com
HAIFA, Israel – April 10, 2025 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a patent covering the Company’s immune cell expansion technologies. This patent specifically includes MAIT cells, a unique subset of T cells that are crucial in helping the body fight infection and repair tissue. Additionally, Pluri was issued a patent in Israel, which mirrors previously granted US patent. Pluri’s total intellectual property (“IP”) estate now includes over 250 patents pending, allowed, and granted.
Pluri’s placental MAIT cells are unique, unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical need. MAIT cells offer unique advantages compared to conventional T cells, holding immense potential for immunotherapy, but until now, their expansion has been a challenge, primarily due to the difficulty in expanding them outside of the human body. Leveraging two decades of cell expertise, Pluri believes that it has overcome the challenge to unlock the full potential of MAIT cells.
The granted patents titled “System and Methods For Immune Cells Expansion and Activation In Large Scale” focus on a system and method for culturing and/or activating immune cells in a large scale, within Pluri’s proprietary 3D cell expansion bioreactors.
“These latest granted patents, which further fortify our growing IP around MAIT cells, are very timely as the U.S. Food and Drug Administration has recently approved Tumor-infiltrating lymphocytes (TILs) and T Cell Receptor-engineered T cell (TCR-T) therapies for the treatment of solid cancers. We believe that MAIT cells represent an emerging field with significant potential in immunotherapy and we believe that our unmatched ability to scale production of MAIT cells, combined with our growing IP portfolio, position Pluri for collaborations that can potentially deliver immune therapies to people in need,” stated Yaky Yanay, Chief Executive Officer and President of Pluri. “We foresee the potential to further develop and bring to market our own proprietary placental-derived MAIT cell immunotherapy platform to revolutionize solid tumor treatment, as well as supporting others in commercializing their immunotherapy treatments.”
Pluri’s Placental Allogeneic MAIT Platform
Offering substantial potential benefits compared to conventional T cells, Pluri’s MAIT cells are isolated from the human placenta, a source rich in highly potent allogeneic immune cells. These cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing Graft versus Host Disease, a significant advantage over other potential allogeneic products, but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy.
When combined with Pluri’s 3D cell expansion technology, we believe that the MAIT platform will enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patients.
About Pluri’s 3D Immune Cell Expansion Technology
Pluri’s novel technology represents a paradigm shift in immune cell expansion methodologies because, unlike traditional approaches, its method employs a fundamentally different concept. Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. We believe that this innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a potentially promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers Contract Development and Manufacturing Organization services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential of its MAIT platform and its ability to enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patients; the potential size of the global immune cell engineering market and the global cancer immunotherapy market; the belief that it unlocked the full potential of MAIT cells; the belief that the immunotherapy field will emerge; the belief that its IP portfolio will grow; the expectation that its own proprietary placental-derived MAIT cell immunotherapy platform will continue to develop, revolutionize solid tumor treatment and support others in commercializing their immunotherapy treatments; and the potential of Pluri’s 3D immune expansion technology as a solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Berry Brady at berry@quantum-corp.com
Haifa, Israel – March 5, 2025 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it has signed an exclusive collaboration agreement with Hemafund Ltd. (“Hemafund”), a Ukrainian umbilical cord blood bank with clinical and research laboratories and facilities specializing in cell preservation and cryostorage (the “Collaboration” or the “Collaboration Agreement”). This Collaboration aims to establish a strategic initiative for stockpiling, distribution, and potential clinical advancement of Pluri’s innovative PLX-R18 cell therapy (“PLX-R18”) as a countermeasure against Hematopoietic Acute Radiation Syndrome (“H-ARS”) in Ukraine. Subject to certain conditions, the Collaboration Agreement will be effective for an initial period of three years and can be extended by the parties for an additional period of three years.
Pursuant to the Collaboration Agreement, Pluri will produce and supply PLX-R18 as a potential treatment for H-ARS following nuclear radiation exposure. Hemafund will leverage its infrastructure and expertise in biostorage, logistics, and regulatory processes to support local distribution and ensure compliance with Ukrainian and European biobank standards. The parties will seek funding to build the necessary capacity of PLX-R18 and expect to enter into a specific separate definitive agreement once such funding becomes available.
This Collaboration comes in response to recent escalations, including a recent Russian drone strike on the Chernobyl nuclear power plant, which caused a fire in the containment shell. Although the blaze was extinguished without an increase in radiation levels, the incident underscores the critical need for effective and readily available radiation countermeasures in the region.
As part of this Collaboration, Pluri and Hemafund will work toward securing external funding to build an initial capacity of 12,000 doses of PLX-R18, ensuring preparedness for radiation-related emergencies. The PLX-R18 doses will be stored and managed by Hemafund, leveraging its state-of-the-art biobank infrastructure and logistics network to enable rapid deployment in case of need.
The Collaboration, if successful, could potentially generate over $100 million in value for both parties, based on the estimated cost per dose and the projected stockpile of 12,000 doses, which is expected to be sufficient to treat 6,000 individuals (as each patient is expected to require two doses). The calculation of 12,000 doses is based on the actual availability of countermeasures in the U.S. Strategic National Stockpile for the U.S. population. This approach aligns with established preparedness measures designed to ensure the availability of countermeasures against H-ARS in response to public health emergencies[1].
H-ARS is caused by exposure to life-threatening amounts of ionizing radiation, such as those which may occur during a radiological or nuclear accident, terrorist activities, and/or warfare. The condition is characterized by a dose-dependent bone marrow suppression, leading to severe neutropenia, thrombocytopenia, anemia, and a heightened risk of mortality.
Strategic Goals of the Collaboration:
“As a company committed to leveraging cell-based technology for humanity’s greatest challenges, we see this Collaboration as a proactive measure to ensure our PLX-R18 therapy is readily available where it is needed,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “We believe that Hemafund’s deep-rooted expertise in Ukraine’s biotech landscape makes them an ideal partner to facilitate local accessibility, storage, and regulatory integration of our solution.”
Yaroslav Issakov, Founder of Hemafund Ltd., added, “We are excited to combine our efforts with Pluri to address this urgent medical need together. We believe that our state-of-the-art cryostorage facilities and logistics network position us well to support the introduction of PLX-R18 as a potential vital tool for radiation emergency preparedness in Ukraine. While we hope such treatments remain precautionary, our goal is to stand ready to distribute this potential therapy in the event of an emergency.”
About Hemafund
Hemafund is a family cord blood bank, located in a biotechnological complex in Ukraine, and specializing in the preservation of umbilical cord blood, placenta, and umbilical cord tissues. The company also provides long-term cryostorage services for human cells and tissues, with a focus on stem cell preservation. Hemafund operates a comprehensive facility that includes facilities such as clinical diagnostic laboratories, processing laboratories, and cryostorage facilities, and is a member of the international Cord Blood Association, coordinating a nationwide program for the application of cord blood in Ukraine. Learn more at https://international.hemafund.com/
About PLURI
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the regenerative medicine, foodtech and agtech fields. The Company also offers Contract Development and Manufacturing Organization services. Pluri establishes partnerships that are aimed to leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential benefits of the Collaboration and each party’s obligation pursuant to the Collaboration Agreement, the potential for PLX-R18 to be used for the potential treatment of H-ARS, the potential doses required and potential revenue to be derived from the Collaboration, the potential for both parties to secure necessary funds to build the necessary capacity of PLX-R18 and the expectation of the parties to enter into a separate definitive agreement when such funds become available. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Or Erez at Or.Erez@gitam.co.il
U.S. Media: Jennifer Ringler at jringler@quantum-corp.com
1 HHS boosts stockpile of products to treat acute radiation syndrome | HHS.govBARDA Awards $37.6 million Contract to Sanofi to Supply Leukine® (sargramostim) for Potential Public Health Emergency | Business WireGoLocalProv | U.S. Shells Out $290M to Stockpile Radiation Sickness Pills — Made by Amgen
HAIFA, Israel – February 4, 2025 –Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the pricing of a private placement of $3.5 million by long-term shareholder Merchant Adventure Fund, L.P., a major existing shareholder of Pluri, under the same terms as the previously announced investment by Alejandro Weinstein.
Pursuant to a securities purchase agreement between the Company and Merchant Adventure Fund, L.P., the Company has agreed to issue and sell 759,219 shares of the Company’s common shares, at a purchase price of $4.61 per Common Share and warrants to purchase up to 45,553 common shares at an exercise price of $5.568 per share, for aggregate gross proceeds of $3.5 million to Pluri. The closing of the offering is expected to occur on or about February 20, 2025, subject to the satisfaction of certain customary closing conditions.
With this latest commitment, Pluri has successfully secured a total of $10 million in strategic investments over the past two weeks. This includes current $3.5 million investment from Merchant Adventure Fund and the $6.5 million investment from Alejandro Weinstein, which also involves Pluri entering into an agreement to acquire Kokomodo Ltd., subject to shareholder approval, and potentially enter the cacao market.
The Company believes that the continued investment from a major, long-term shareholder is a strong vote of confidence in Pluri’s vision, technology, and execution strategy. These funds are expected to support the Company’s growth as a global leader in cell-based technology, reinforcing its ability to expand across multiple industries, including pharma, foodtech, and agtech.
“I believe that the additional investment from one of our largest shareholders reaffirms the strength of Pluri’s strategy and the trust of our long-term investors in our ability to execute,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “We believe that we are well-positioned to advance our mission of leveraging our cell-based technology platform to revolutionize multiple industries.”
The Company believes that this investment further strengthens Pluri’s financial position as it continues to drive innovation, scale its platform, and unlock new market opportunities.
The securities described above were offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the regenerative medicine, foodtech and agtech fields. The Company also offers Contract Development and Manufacturing Organization services. Pluri establishes partnerships that are aimed to leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expected closing of the offering, the receipt of the proceeds and the intended use of the proceeds from the offering, the belief that the investment is a strong vote of confidence in Pluri’s vision, technology, and execution strategy and its ability to execute. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: the conditions to the closing of the Transactions, including shareholder approval, may not be met; the parties may not successfully negotiate final documentation with respect to the Kokomodo Transaction; the expected benefits from the Transactions may not be realized; changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.